Blockchain Registration Transaction Record

Soligenix's HyBryte Shows Promise in CTCL Treatment

Soligenix (SNGX) highlights HyBryte(TM)'s success in treating CTCL, showing 75% efficacy at 18 weeks. A breakthrough in cancer treatment offering hope and innovation.

This news is significant for patients suffering from early-stage cutaneous T-cell lymphoma (CTCL) and the broader medical community. HyBryte(TM) represents a potentially safer, more effective treatment option compared to existing therapies, which often come with severe side effects. The success of this treatment could revolutionize the approach to managing CTCL, offering patients a better quality of life and hope for long-term remission. Additionally, Soligenix's work in developing treatments for other rare diseases and vaccines underscores the company's role in addressing critical health challenges, making this news relevant not just to CTCL patients but to anyone interested in advancements in medical science and public health.